Isotope technology firm Eckert & Ziegler has posted financial results for the nine-month period ending 30 September.
The company saw revenues of 103.1 million euros ($114.4 million U.S.), on par with 2015's 102.7 million euros ($113.9 million U.S.). Net income for the period fell 16%, from 9.8 million euros ($10.8 million U.S.) in 2015 to 7.8 million euros ($8.6 million U.S.).
The company's greatest revenue increase came from its Radiopharma segment, which saw revenues of 29.3 million euros ($32.5 million U.S.), compared with 26.2 million euros ($29 million U.S.) in 2015. Its Isotope Products segment saw revenues of 58.2 million euros ($64.5 million U.S.), compared with 56.5 million euros ($62.7 million U.S.) last year. Finally, Radiation Therapy revenues fell from 21.6 million euros ($23.9 million U.S.) in 2015 to 17.8 million euros ($19.7 million U.S.) due to the sale of two of the company's divisions in 2015.
